In acute myeloid leukemia (AML), the targeting of the FLT3 and BCL-2 pathways has indirectly diminished leukemic stem cells, leading to significant enhancements in survival with medicines like venetoclax. The gene discussed is FLT3; the disease is acute myeloid leukemia.